HOME > Investors > Press Releases
Subject Progression of Business Plans in 2014
Writer ViroMed
Date 2014/01/16

Progression of Business Plans in 2014

1. Business Plans

Abstract

ViroMed Co., Ltd. is a biopharmaceutical/herbal medicine and nutraceutical development company

Prerequisite

- The prerequisites to successfully developing biopharmaceutical and having global competitiveness are securing funding and patent protection for proprietary technology

- Because ViroMed’s business is drug related, the FDA strictly regulates the development/manufacture/clinical study/licensing/distribution/sales of the products

Objectives

(First Half of 2014)

1. VM202-PAD (CLI) (Peripheral Artery Disease)

-Submit phase II final report & present data at academic conference in the US (US, Korea)

-100% phase II patient enrollment (China)

2. VM202-DPN (Diabetic Peripheral Neuropathy)

-Complete follow-up of phase II patients (105 subjects) & begin data analysis (US, Korea)

3. VM206 (Breast Cancer)

-Present phase I data in an academic conference & finalize plans for phase II clinical study (Korea)

4. HX106 (Improve Memory)

-Launch product as dietary supplement & submit application for functional health claim (Korea)

Investment Plans

- KRW 1.51 billion in the first half and KRW 820 million in the second half for manufacturing clinical study samples (includes VM202 and VM206)

- KRW 2.88 billion in the first half and KRW 990 million in the second half for VM202 related clinical study

- KRW 100 million in the first half and KRW 200 million in the second half in R&D for investigating new substance

- KRW 60 million in the first half for launching dietary supplement & herbal based medicine development

2. Progression

Achievement Rate for Objectives of Second Half of 2013

Biologics

Indication

Country

Objectives

Achievement Rate

VM202-PAD

(CLI)

Critical Limb Ischemia

US, Korea

(Phase II) Complete final report

85%

China

(Phase II) Complete 80% of patient enrollment

86%

VM202-DPN

Diabetic Peripheral Neuropathy

US, Korea

(Phase II) Complete 9 month follow-up of 20% of 105 subjects

100%

VM206

Breast Cancer

Korea

(Phase I) Complete final report

100%

HX106

Improve Memory

Korea

(Human Trial) Complete final report

100%

 

[Earnings Forecast in 2014] 


2014

Revenue (KRW Million)

6,154

Operating Income 

(KRW Million)

474

Basis for Forecast

- Milestone payment: expecting 4.277 (KRW billion) in revenue through milestone achievement for various projects

- Dietary supplement sales : expecting 1.257 (KRW billion) in revenue, similar to previous year

- Raw material sales: expecting 620 (KRW million) in revenue

 (Report date: 2014.01.15)